Page 1 | Search Results | Blood | American Society of Hematology

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Anti-CD38-CAR IPS-Derived Cytotoxic T Lymphocytes Efficiently Eliminate Myeloma Cells Treated with Daratumumab and Isatuximab in Vitro and In Vivo

Yuji Hattori, Takanori Kubo, Seiji Nagano, Takahiko Miyama, Yoshitaka Taniguchi, Yoshitaka Iba, Nobuko Ohshima, Rie Kanehara, Takakazu Kawase, Masahide Takahashi, Hiroshi Kawamoto, Keichiro Mihara

Blood (2023) 142 (Supplement 1): 3312.

https://doi.org/10.1182/blood-2023-173356

Published: 2023

Journal Articles

Regeneration of Tumor Antigen Specific CTLs Utilizing iPSC Technology for Off-the-Shelf Immunotherapy

Takuya Maeda, MD, Seiji Nagano, MD, Kyoko Masuda, PhD, Toshio Kitawaki, MD PhD, Keisuke Kataoka, MD PhD, Seishi Ogawa, MD PhD, Norimitsu Kadowaki, MD PhD, Akifumi Kondo Takaori, MD PhD, Hiroshi Kawamoto, MD PhD

Blood (2016) 128 (22): 4554.

https://doi.org/10.1182/blood.V128.22.4554.4554

Published: 2016

Journal Articles

Prognostic Factors of Elderly Diffuse Large B-Cell Lymphoma Treated with R-CHOP: Performance Status and Age Over Eighty, but Neither Lactate Dehydrogenase Level, Stage, Nor Relative Dose Intensity Delivered, Associated with Clinical Outcome

Kazunari Aoki, MD, June Takeda, MD, Yuki Hunayama, MD, Nobuhiko Yamauchi, MD, Aiko Kato, MD, Yuichiro Ono, MD, Hiroshi Arima, MD, Yoko Takiuchi, MD, Seiji Nagano, MD, Sumie Tabata, MD, PhD, Akiko Matsushita, MD, Takayuki Ishikawa, MD, PhD

Blood (2011) 118 (21): 1610.

https://doi.org/10.1182/blood.V118.21.1610.1610

Published: 2011

Journal Articles

Impact of Occult Bone Marrow Involvement on Outcome in Diffuse Large B-Cell Lymphoma Treated with R-CHOP

Hiroshi Arima, MD, Hayato Maruoka, Koji Nasu, Yuki Funayama, MD, June Takeda, MD, Nobuhiko Yamauchi, MD, Kazunari Aoki, MD, Aiko Kato, MD, Yuichiro Ono, MD, Seiji Nagano, MD, Yoko Takiuchi, MD, Sumie Tabata, MD, PhD, Akiko Matsushita, MD, Yukihiro Imai, MD, PhD, Takayuki Takahashi, MD, PhD, Takayuki Ishikawa, MD, PhD

Blood (2011) 118 (21): 1578.

https://doi.org/10.1182/blood.V118.21.1578.1578

Published: 2011

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Anti-CD38-CAR IPS-Derived Cytotoxic T Lymphocytes Efficiently Eliminate Myeloma Cells Treated with Daratumumab and Isatuximab in Vitro and In Vivo

Regeneration of Tumor Antigen Specific CTLs Utilizing iPSC Technology for Off-the-Shelf Immunotherapy

Prognostic Factors of Elderly Diffuse Large B-Cell Lymphoma Treated with R-CHOP: Performance Status and Age Over Eighty, but Neither Lactate Dehydrogenase Level, Stage, Nor Relative Dose Intensity Delivered, Associated with Clinical Outcome

Impact of Occult Bone Marrow Involvement on Outcome in Diffuse Large B-Cell Lymphoma Treated with R-CHOP

Email alerts

ASH Publications

American Society of Hematology

Update search

Anti-CD38-CAR IPS-Derived Cytotoxic T Lymphocytes Efficiently Eliminate Myeloma Cells Treated with Daratumumab and Isatuximab in Vitro and In Vivo

Regeneration of Tumor Antigen Specific CTLs Utilizing iPSC Technology for Off-the-Shelf Immunotherapy

Prognostic Factors of Elderly Diffuse Large B-Cell Lymphoma Treated with R-CHOP: Performance Status and Age Over Eighty, but Neither Lactate Dehydrogenase Level, Stage, Nor Relative Dose Intensity Delivered, Associated with Clinical Outcome

Impact of Occult Bone Marrow Involvement on Outcome in Diffuse Large B-Cell Lymphoma Treated with R-CHOP

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only